ASSESSMENT OF THE EFFECTS OF ORAL ESTROGEN AND TRANSDERMAL ESTROGEN ON SEVERAL COAGULATION FACTORS OF FROZEN EMBRYO TRANSFER CYCLES IN THE MILITARY INSTITUTE OF CLINICAL EMBRYOLOGY AND HISTOLOGY

Thị Nguyệt Phạm, Quốc Thành Trịnh , Thế Sơn Trịnh, Trọng Hà Đinh1,
1 Học viện Quân y

Main Article Content

Abstract

Objectives: To assess the effects of oral estrogen and transdermal estrogen on several coagulation factors in endometrial preparation (EP) of frozen embryo transfer cycles. Methods: A prospective descriptive study on 49 couples with indications for frozen embryo transfer at the Military Institute of Clinical Embryology and Histology from October 2021 to July 2022. Subjects were randomly divided into two groups. Group one used oral estradiol, and group two used transdermal estradiol. PT(s), aPTT(s), and Antithrombin III(%) index were assessed before and after EP with exogenous estradiol in 2 groups. Results: Before EP, the PT, APTT, and AT III were not different between the two groups (p > 0.05); in group one, APTT after EP (29.35 ± 1.72) was lower than before EP (30.63 ± 1.52) with statistical significance (p < 0.05), while PT, AT III, has no difference (p > 0.05); in group two, APTT post-EP (30.24 ± 1.72) was lower than pre-EP (31.03 ± 2.26) with statistical significance (p < 0.05), while PT, AT III  has no difference (p > 0.05); in the uterine EP stage, PT, APTT, AT III had no difference between two groups (p > 0.05). Conclusion: APTT after EP was significantly lower than before EP, which was statistically significant in the two groups. There was no difference between the two groups in coagulation indices such as PT, APTT, and AT III.

Article Details

References

1. WHO. Scientific group meeting on cardiovascular disease and steroid hormone contraceptives. Wkly Epidemiol Rec. 1997; 72(48):361-363.
2. Todd J., Lawrenson R., Farmer R.D., et al. Venous thromboembolic disease and combined oral contraceptives: A re-analysis of the MediPlus database. Hum Reprod. 1999; 14(6):1500-1505.
3. Jick H., Jick S.S., Gurewich V., et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet. 1995; 346(8990):1589-1593.
4. Middeldorp S., Meijers J.C., van den Ende A.E., et al. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: A cross-over study. Thromb Haemost. 2000; 84(1):4-8.
5. Beller F.K. và Ebert C. Effects of oral contraceptives on blood coagulation. A review. Obstet Gynecol Surv. 1985; 40(7):425-436.
6. Shahrokh Tehraninejad E., Kabodmehri R., Hosein Rashidi B., et al. Trans dermal estrogen (oestrogel) for endometrial preparation in freeze embryo transfer cycle: An RCT. Int J Reprod Biomed. 2018; 16(1):51-56.
7. Bagot C.N., Marsh M.S., Whitehead M., et al. The effect of estrone on thrombin generation may explain the different thrombotic risk between oral and transdermal hormone replacement therapy. J Thromb Haemost. 2010; 8(8):1736-1744.
8. Antovska V., Dimitrov G., Jovanovska V., et al. The influence on coagulation of transdermal estrogen hormone replacement therapy as a preoperative preparation of the tissue before vaginal hysterectomy. Prilozi. 2004; 25(1-2):95-102.